JPRN-UMIN000001984已完成未知
Evaluation of Ranibizumab for diabetes macular edema - Evaluation of Ranibizumab for diabetes macular edema
Yamagata University faculty of Medecine,department of ophthalmology0 个研究点目标入组 10 人开始时间: 2010年10月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Tha patients who has history of myocardial infarction and brain infarction.
研究者
相似试验
进行中（未招募）
1 期
RELIGHT - Ranibizumab treatment of diabetic macular oEdema with bimonthLy monItorinG after a pHase of initial Treatment. A UK, 18-month, prospective, open-label, multicenter, single-arm Phase IIIb study, with 12-month primary endpoint, assessing the efficacy and safety of Lucentis (Ranibizumab) in patients with visual impairment due to diabetic macular oedema.EUCTR2010-022616-39-GBovartis Pharmaceuticals UK Ltd
已完成
2 期
Ranibizumab for Edema of the Macula in Diabetes: Protocol 3 With High Dose - the READ 3 StudyDiabetic Macular EdemaNCT01077401Johns Hopkins University152
已完成
2 期
The Ranibizumab for Edema of the mAcula in Diabetes-2 (READ-2) StudyDiabetic Macular EdemaNCT00407381Johns Hopkins University126
已完成
不适用
Ranibizumab 0.5 mg for Diabetic Macular Edema With Initial Intensive Treatment in the Real World Clinical Setting in Korea (Rising K)Diabetic Macular EdemaNCT05815212Novartis Pharmaceuticals87
撤回
2 期
Ranibizumab as a Rescue Therapy for Diabetic Macular EdemaDiabetic Macular EdemaNCT01253694New England Retina Associates